We are a Specialty Pharmaceutical Company with a Focus in Pain and Addiction

BEMA® Technology

A small, dissolvable polymer film for application to mucosal membranes (inner lining of cheek) which allows for transmucosal delivery of drugs.

 

CURRENT INVESTOR PRESENTATION, DATED AUGUST 4, 2015

BDSI Reports Second Quarter 2015 Financial Results

Monday, August 10, 2015, 8:00 a.m.

Replay available until August 24, 2015

Domestic:  888-438-5524

International:  719-325-2435

Conference ID:  1010257

Webcast: http://public.viavid.com/player/index.php?id=115388

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces FDA Approval of New Formulation of ONSOLIS® (fentanyl buccal soluble film) CII
Approval of new formulation expected to allow ONSOLIS to return to U.S. market in 2016


BioDelivery Sciences Strengthens Sales Force Leadership with Hiring of Scott Plesha, Former Salix Head of Sales
Plesha to Lead BUNAVAIL Sales Effort; Joins BDSI Following 13 years in Building and Managing the Salix GI Sales Force